MSMichael W. Sill
Michael W. Sill
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael W. Sill has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Carol Aghajanian
Memorial Sloan Kettering Cancer Center, New York, NY, United States of America
3 shared publications - Bradley Monk
Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA
2 shared publications - Krishnansu Sujata Tewari
University of California, Irvine, CA, United States of America
2 shared publications - Michael J. Birrer
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA
2 shared publications - Paul A. DiSilvestro
Women and Infants Hospital in Rhode Island/The Warren Alpert Medical School of Brown University, Providence, RI
2 shared publications - Adam D. Pfefferle
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA
1 shared publication
Latest Publications
- 8 March 2025
- Published by Elsevier in Gynecologic Oncology
- Vol. 195, 66-74
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study
- 8 March 2025
- Published by Elsevier in Gynecologic Oncology
- Vol. 195, 66-74
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study
- Open Access
- 8 March 2023
- Published by Elsevier in Gynecologic Oncology
- Vol. 171, 141-150
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study
- 8 March 2023
- Published by Elsevier in Gynecologic Oncology
- Vol. 171, 141-150
Open AccessFinal survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study
- 26 July 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 159 (1) , 79-87
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study
- 26 July 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 159 (1) , 79-87
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study
- 1 December 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 155 (3) , 420-428
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study
- 1 December 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 155 (3) , 420-428
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study